Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia

(2015) Eliano Pio Navarese et al.   ANNALS OF INTERNAL MEDICINE

Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?Response to Hovingh et al

(2015) G. Kees Hovingh et al.   CIRCULATION

Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk?Response to Barter et al

(2015) Philip J. Barter et al.   CIRCULATION

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects

(2015) John S. Millar et al.   JOURNAL OF CLINICAL INVESTIGATION

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

(2015) John J P Kastelein et al.   LANCET

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

CETP inhibitors downregulate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 dependent mechanism

(2014) Bin Dong et al.   ATHEROSCLEROSIS

Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters

(2014) François Briand et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study

(2014) Antonio M. Gotto et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events

(2014) Anand Rohatgi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression

(2014) Navjot Kaur et al.   PLoS One

Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients

(2014) D. Keene et al.   BMJ-British Medical Journal

How Anacetrapib Inhibits the Activity of the Cholesteryl Ester Transfer Protein? Perspective through Atomistic Simulations

(2014) Tarja Äijänen et al.   PLoS Computational Biology

Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children

(2013) Michael M. Page et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   CIRCULATION

Update on the Discovery and Development of Cholesteryl Ester Transfer Protein Inhibitors for Reducing Residual Cardiovascular Risk

(2013) Nathan B. Mantlo et al.   JOURNAL OF MEDICINAL CHEMISTRY

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

(2012) Benjamin F Voight et al.   LANCET

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

(2012) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evacetrapib

(2012) Stephen J. Nicholls   Current Cardiology Reports

Model-Based Development of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor

(2011) Rajesh Krishna et al.   AAPS Journal

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis

(2011) Meng Lee et al.   ATHEROSCLEROSIS

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

(2011) et al.   EUROPEAN HEART JOURNAL

Anacetrapib, a cholesteryl ester transfer protein inhibitor

(2011) Amanda J Hooper et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters

(2011) Jose Castro-Perez et al.   JOURNAL OF LIPID RESEARCH

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib

(2010) Laurent Yvan-Charvet et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects

(2010) Amit Garg et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

(2010) Min Jun et al.   LANCET

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

(2009) Rajesh Krishna et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans

(2009) S. Kumar et al.   DRUG METABOLISM AND DISPOSITION

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

(2008) Daniel Bloomfield et al.   AMERICAN HEART JOURNAL

Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

(2008) R Krishna et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Assessment of the CYP3A-Mediated Drug Interaction Potential of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Volunteers

(2008) Rajesh Krishna et al.   JOURNAL OF CLINICAL PHARMACOLOGY